SEINE BIO · SCIENCE LIBRARY
Maridebart cafraglutide / MariTide
MariTide is the development name for maridebart cafraglutide, an antibody-peptide conjugate combining GLP-1 agonism with GIP receptor antagonism.
Research compoundA closer look at the research, the uncertainties and the questions worth asking.
THE FULL READING GUIDE · UPDATED OCTOBER 7, 2026
Inside the science of Maridebart cafraglutide / MariTide.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Overview
Maridebart cafraglutide, commonly called MariTide, is an investigational antibody-peptide conjugate for weight management. Its design and longer research dosing intervals attract attention from people seeking a different treatment experience. A convenient interval is only one part of care; effectiveness, tolerability, and approval status still determine whether a product is a real clinical option.
Community Use
Online comparisons often emphasize less frequent administration or describe MariTide as an upgrade to existing medicines. Those are hypotheses to evaluate rather than established benefits for every patient. No exact profile was located in the two requested community catalogs during this review, so the community section does not supply an invented vial or maintenance protocol.
Doses, Durations & Cycles
Informal biohacking protocols and published regimens. Attributed website reports for education, not medical recommendations. Multiple publications document circulation; they do not establish a safe dose or validate a cycle.
| Route / formulation | Dose / reported phases | Frequency | Duration / break | Notes and source |
|---|---|---|---|---|
| Subcutaneous injection | Trial arms: 140, 280 or 420 mg every 4 weeks; 420 mg every 8 weeks; additional 420 mg every-4-week target arms used escalation. | Every 4 or 8 weeks in the cited trial | 52-week treatment period Break: No informal off-cycle established by this source | Human study regimen Jastreboff et al., NEJM 2025; once-monthly maridebart cafraglutide phase 2 trial |
| Subcutaneous | Chart calls 140 mg an initiation step, 280 mg escalation and 420 mg target dosing. | Every 4 weeks | No fixed total course in chart; clinical discussion cites 52-week trial outcomes. Break: Not stated | Published informal biohacking claim PeptideDosage |
| Subcutaneous | 140–420 mg, described as titrated research reference doses. | Monthly; elsewhere defined as every 4 weeks | No informal course stated; the page separately mentions 52-week phase 2 results. Break: Not stated | Published informal biohacking claim Peptide Reference |
Important context: A 1–10 mg weekly schedule is unsupported by this primary trial. Doses were in the hundreds of mg at monthly or longer intervals; these arms do not establish a clinical safe maximum.
Sources checked October 7, 2026. Educational listing does not establish prescribing approval or availability through Seine Bio.
The phase 2 study investigated several dosing schedules and escalation strategies over 52 weeks. These arms are tied to a sponsor-controlled antibody-peptide product, not a consumer on/off cycle. A long-acting molecule also cannot be compared with weekly drugs solely by dividing total milligrams by the number of weeks.
Research Findings
A 2025 randomized phase 2 study enrolled 592 participants across groups with obesity, including a cohort with type 2 diabetes. Investigators compared different investigational regimens with placebo over one year. This is substantive human research, while still preceding an approved prescribing framework. Human phase 2 publication.
U.S. Approval & Access
MariTide remains investigational in this source review; an FDA-approved routine weight-management product was not established. A development name, clinical result, or proposed program price is not an approval or a supply commitment. A clinician may discuss the research while recommending an appropriate available treatment.
What It Does in the Body
The conjugate combines GLP-1 receptor agonism with GIP receptor antagonism. That differs from tirzepatide’s dual agonist approach despite some shared receptor names. Opposite actions at one receptor cannot be treated as a minor branding difference; each product needs direct clinical evidence rather than a mechanism-based assumption of equivalence. A longer research interval does not establish a reliable personal onset, peak clinical benefit, or duration of benefit; those depend on the actual product and clinical evidence.
Benefits & Reported Experiences
The trial demonstrated meaningful average weight reductions relative to placebo. Average outcomes describe a studied population, not a promise for an individual. Cross-trial rankings can be misleading because participant characteristics, dose strategies, missing-data methods, and treatment duration may differ between programs.
Side Effects & Risks
Gastrointestinal adverse events and treatment discontinuation were important tolerability considerations in the phase 2 study. Less frequent dosing should not be interpreted as fewer side effects. For a long-acting investigational product, future evidence must clarify both sustained benefit and how adverse effects are managed.
Delivery Options
The study used subcutaneous administration of a particular investigational conjugate. It does not support substituting a similarly named research vial or transferring instructions from another weight-loss medicine. Product architecture and duration of exposure are part of the treatment being tested; this page provides no self-administration instructions.
Product Quality & Storage
For an antibody-peptide conjugate, manufacturing identity and biological function matter beyond a simple purity percentage. A supplier claim does not prove equivalence to the sponsor’s trial material. Questions about approved supply, storage, and dispensing can only be resolved for a specific authorized product and a real patient-care pathway. A sponsor’s conjugate has study-specific handling controls. No retail storage directions are guessed for a MariTide-like research preparation.
Combinations & Interactions
No consumer combination with tirzepatide, semaglutide, or amylin candidates is supported by the cited MariTide trial. Shared pathways can create overlap rather than extra benefit. Discussion of future combinations should identify the actual trial and avoid converting a list of promising molecules into a do-it-yourself regimen.
Talking With Your Provider
A weight-management consultation can compare your goals with options that have an appropriate clinical and legal pathway. If less frequent medication is your main interest, explain why: convenience, adherence, cost, or prior side effects may lead to different recommendations. Participation in any research program remains subject to the study team’s decisions.
Educational purpose only. Not medical advice. Consult licensed provider. Obtain from authorized compounding pharmacies only.
Compounding is appropriate only when lawful for the specific substance and patient; some substances may be unavailable. Finished FDA-approved medicines may also be dispensed by licensed non-compounding pharmacies.
Questions about what you read?
Explore the research library Create a free account
Educational information only. A free account lets you request review of your care goals. This profile does not establish availability, clinical suitability or access to the named compound.
Explore clinically appropriate options with a licensed provider. Inquiry does not guarantee a prescription, research-program acceptance or access to a particular substance.
Questions worth bringing to your appointment.
- Are there alternatives that address my goal?
- If treatment is appropriate, what monitoring and follow-up would I need?
- Could my health history or current medicines change the risks?
Saved discussion topics 0
Save topics you would like to discuss with your healthcare provider. Saving is an expression of interest, not a treatment request or medical recommendation.
Saved only in this browser, on this device—not in a patient account. Other people using this browser may see your list. Clear it when using a shared device. This list is not sent to our team.
Explore your next step with SEINE BIO.
Bring your questions to a wellness consultation. Inclusion in this library does not indicate prescribing or product availability. A consultation does not guarantee a prescription.
Explore consultations Back to Metabolic health & weight-management scienceEducational information · U.S. context · October 7, 2026. No ordering, personalized dosing or injection instructions.
Bring your saved topics to your care team.
Members can select up to five favorites and send a message for review. Your saved list stays in this browser until you choose what to submit.
Choose saved topics for review →